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Abstract
The PI3K-dependent activation of AKT results in the inhibition of GSK3β in most signaling
pathways. These kinases regulate multiple neuronal processes including the control of syn-
apse number as shown for Drosophila and rodents. Alzheimer disease’s patients exhibit
high levels of circulating GSK3β and, consequently, pharmacological strategies based on
GSK3β antagonists have been designed. The approach, however, has yielded inconclusive
results so far. Here, we carried out a comparative study in Drosophila and rats addressing
the role of GSK3β in synaptogenesis. In flies, the genetic inhibition of the shaggy-encoded
GSK3β increases the number of synapses, while its upregulation leads to synapse loss.
Likewise, in three weeks cultured rat hippocampal neurons, the pharmacological inhibition
of GSK3β increases synapse density and Synapsin expression. However, experiments on
younger cultures (12 days) yielded an opposite effect, a reduction of synapse density. This
unexpected finding seems to unveil an age- and dosage-dependent differential response of
mammalian neurons to the stimulation/inhibition of GSK3β, a feature that must be consid-
ered in the context of human adult neurogenesis and pharmacological treatments for Alzhei-
mer’s disease based on GSK3β antagonists.
Introduction
Glycogen synthase kinase 3 (GSK3) [1,2] is a serine/threonine kinase that regulates neuronal
polarization, neuritogenesis [3], migration, axon growth and guidance [4–8] among other cel-
lular processes. To date, two GSK3 genes (GSK3α and GSK3β) and a neuronal variant of
GSK3β (GSK3β2), [9] have been identified in mammals [10–11]. In rodent adult hippocampus,
GSK3β is more abundant than GSK3α [12] and it increases the most in aged brains [13]. In
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Drosophila larvae, GSK3β is represented by two splice variants (Sgg10 and Sgg39) encoded in
the single gene shaggy (sgg) [14–15]. In this study, all genetic and pharmacological experiments
are referred to GSK3β activity.
The functional requirements of GSK3 are diverse and, consequently, the repertoire of elic-
ited pathologies is extensive. Focusing on the nervous system, in mammalian brains, GSK3 is
required for proliferation, differentiation and neurotransmission in adult neurons [16–20].
GSK3 is detected at both pre- and postsynaptic compartments controlling endocytosis of syn-
aptic vesicles and hence, neurotransmission [21]. In neuronal networks, GSK3 participates in
long-term potentiation and depression (LTP/LTD) [19,22]. Changes in GSK3 levels underlie
pathologies as diverse as muscular dystrophy, cancer and bipolar disorders, as well as autism,
schizophrenia, Fragile X syndrome or Alzheimer’s diseases (AD) [23–26]. AD patients show
high levels of circulating GSK3 [9,27], which has led to GSK3 inhibitor-based strategies to treat
the disease. In spite of this sound rationale, however, the results have not been positive. Here,
we set out a comparative study of the synaptic effects of GSK3 inhibition in Drosophila and
Rattus, aimed to identify possible reasons for the puzzling failure of current AD pharmacologi-
cal approaches.
We have previously identified a phosphoinositide 3-kinase (PI3K) synaptogenic pathway in
Drosophila which is conserved in vertebrates. Activation/inhibition of PI3K or downstream ele-
ments of this pathway coherently regulate the number of synapses [28–29]. While the overacti-
vation of PI3K-AKT signaling results in functional supernumerary synapses both in
Drosophila and mammals [28–30], the overexpression of GSK3 causes a reduction of synapse
number [28,31–32]. The pathway includes also the Jun kinase/AP-1 and Wnt signaling which
are modulated by GSK3 [33]. Likewise, in the granular cells of the rodent cerebellum, Wnt reg-
ulates Synapsin clustering through a Dvl/GSK3 dependent mechanism [34]. Indirect evidences
indicate that GSK3 inhibitors increase Synapsin clustering [7] whereas transient GSK3 overex-
pression decreases Synapsin expression [22].
The molecular mechanisms that sustain these cellular processes involve changes in the
phosphorylation status of specific residues in these kinases. Thus, after PI3K activation, AKT is
phosphorylated in Serine 473 by mTORC2 and in Threonine 308 by PDK1 [35]; which results
in the inhibition of GSK3 by phosphorylation of its Serine 9 [1]. However, GSK3 is an unusual
kinase in the sense that it has a high basal activity at resting conditions. Its activity is down-reg-
ulated by upstream elements in its pathway [36], other kinases, or the phosphorylation status
of their multiple substrates [1,37]. These features could be expected to result in heterogeneous
responses following the experimental manipulation of GSK3 activity.
Here, we show that the downregulation of GSK3 promotes synapse formation in Drosophila
neurons. In rodent hippocampal neurons, however, GSK3 inhibition yields differential results
according to cell culture age and dosage. Young culture neurons show a decrease of synapses
while aged cultures respond with an increase of synapse number. Also, whereas spine density




Flies:. LineD42-Gal4was kindly provided by H. L Atwood (University of Toronto) [38].
Line elav-Gal4 [39],UAS-AKT [40] andUAS-GSK3DN [41] were obtained from Bloomington
Stock Center. TheUAS-PI3K92E (referred here as UAS-PI3K) andUAS-PI3K92ED954A (UAS-
PI3KDN) stocks originate from S. Leevers (Cancer Research Center, London). TheUAS-GSK3RNAi
construct was obtained from the Vienna Stock Center (http://stockcenter.vdrc.at/control/main)
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(reference 101538KK) and theUAS-GSK3 strain was provided by Dr. Manuel Calleja (Centro de
Biología Molecular, Madrid) [15].
Rodent neurons:. Primary hippocampal cultures were obtained from P0 rat pups (Spra-
gue-Dawley, strain, Harlan Laboratories Models SL, France). Animals were anesthetized by hy-
pothermia in paper-lined towel over crushed-ice surface during 2–4 minutes and euthanized
by decapitation. Animals were handled and maintained in accordance with the Council Direc-
tive guidelines 2010/63EU of the European Parliament, and approved by the Ethical Commit-
tee of the CIBIR.
Cell cultures
SH-SY5Y cell cultures:. SH-SY5Y human neuroblastoma cells were purchased from
ATCC (ref: CRL-2266). Cells were seeded at 5x104 cells/cm2 and used 5 days later, usually
when cultures reached a 70–80% confluence. Culture media contained DMEM F-12 Ham
(Sigma-Aldrich, USA) supplemented with 0.5 mM glutamine (Sigma-Aldrich, USA), penicillin
(50 mg/ml)/streptomycin (50 U/ml) from Sigma-Aldrich (USA), and 10% FBS (Sigma-Aldrich,
USA). Cells were serum starved for 16 hours prior to treatment, in order to reduce Akt basal
activity.
Hippocampal neuron cultures:. Primary cultures of hippocampus neurons were prepared
as previously described [42–43]. Glass coverslips (12 mm in diameter) were coated with poly-
L-lysine (100 μg/ml) and laminin (4 μg/ml). Hippocampus neurons were seeded and grown
in Neurobasal (Invitrogen, USA) culture medium supplemented with glutamine 0.5 mM,
50 mg/ml penicillin, 50 units/ml streptomycin, 4% FBS and 4% B27 (Invitrogen, CA, USA), as
described before [29]. After 4, 7, 14 and 21 days in culture, 100 μl (of a total of 500 μl) of culture
medium was replaced by 120 μl of fresh medium. On day 4th, 4 μM cytosine-D-arabinofurano-
side was added to prevent overgrowth of glial cells. Two seeding densities were employed: a
medium-low density of 10x104 neurons/cm2 for immunocytochemistry, and a higher density
of 50x104 neurons/cm2 for biochemical experiments. In both cases, cultured cells were seeded
on plastic 24-wells plates.
Immunohistochemistry, image acquisition and quantification of Drosophila synapse
number. We systematically used the nc82 Mab to identify the active zone component, CAST/
Bruchpilot, of synapses. The matching between presynaptic nc82 and postsynaptic GluRII
immunosignals have been previously documented [44]. Late third instar larvae were dissected,
fixed and processed as previously described [44]. Specimens were incubated overnight at 4°C
in blocking solution with the following primary antibodies: monoclonal antibody nc82 (DSHB,
USA, 1:10) to count individual synapses, and anti-HRP (Jackson ImmunoResearch Laborato-
ries, USA, 1:200), to visualize the neuronal membrane. The following secondary antibodies
were applied for 3 hours at room temperature: Alexa 488 (goat anti-mouse, Molecular Probes,
USA, 1:500) and Alexa 568 (goat anti-rabbit, Molecular Probes, USA, 1:500). Larvae were
mounted in Vectashield (Vector Labs, USA). Confocal Images from muscle fibers 6–7 (seg-
ment A3) were acquired with a Leica Confocal Microscope TCS SP5 II (Mannheim, Germany).
Serial optical sections at 1024x512 pixels (100x50 mm) or 1024x1024 pixels (100x100 mm)
were obtained at 0.5 μmwith the 63x objective. Image J software (version 1.44, http://rsb.info.
nih.gov/ij/, NIH, USA) was used to determine the number of synapses per neuromuscular
junction (NMJ). Individual synapses (nc82 positive puncta) were quantified by using the Point
Picker plug-in as published previously [40]. A minimum of 10–12 larvae from each genotype
were analyzed.
Cell culture immunocytochemistry. Synaptic density on hippocampal cultures was ana-
lyzed as previously described [29]. In short, cultures were rinsed in phosphate buffer saline
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PLOSONE | DOI:10.1371/journal.pone.0118475 March 12, 2015 3 / 24
(PBS) and fixed for 30 min in 4% paraformaldehyde-PBS. Coverslips were incubated overnight
in blocking solution with the following antibodies: anti-Bassoon monoclonal mouse antibody
(ref. VAM-PS003, Stress Gen, USA) and rabbit polyclonal sera against Synapsin (ref. 2312, Cell
Signaling, USA). Samples were incubated with a fluorescence-conjugated secondary antibody
in PBS for 30 min. After that, coverslips were washed three times in PBS and mounted using
Mowiol (all secondary antibodies from Molecular Probes-Invitrogen, USA). Stack images
(pixel size 90 nm with 0.5 μm Z step) were obtained with a Leica SP5 Confocal microscope.
Image J (version 1.47) “deconvolution Acoloma macro” plugin was used to process the images
before analysis. Synaptic density and dendritic length quantification was done manually with
Image J software. To reduce variability among different cultures and treatments, synaptic
puncta were counted in proximal dendrites only, starting from a clearly identified neuronal cell
soma. Synaptic density represents the number of synapses per 100 μm of dendritic length. Per-
centage of synaptic change is the average of different cultures under the same experimental
conditions. As a control, we used sister untreated cultures growing in the same multi-well
plate.
Transfection and image analysis of spines in rat hippocampal cultures. Neuronal GFP-
Actin expression was obtained by electroporation before plating, employing a BioRad Cell elec-
troporator system. Approximately 4x106 cells and 10 μg of plasmid were mixed in BioRad elec-
troporation buffer (BioRad). An exponential discharge protocol (220 V, 950 μF, resistance
fixed to infinitum) was employed. Spines were visualized by transfection with a plasmid encod-
ing the GFP protein fused to chick β-actin under the control of the platelet-derived growth fac-
tor promoter region (kindly provided by Y. Goda, MRC Cell Biology Unit, University College
London, London, UK) [45]. Transfected cultures were fixed with 4% paraformaldehyde-PBS,
washed and mounted in Mowiol. Images were obtained in a Leica SP5 Confocal, acquired in
stacks (pixel size 60 nm with 0.1 μm Z step) and processed as above. Spine density represents
the number of spines per 100 μm of dendritic length.
Western blots. For Drosophila samples, nitrocellulose membranes were incubated with
the following primary antibodies: mouse anti-GSK3 (detecting both Drosophila GSK3 splice
variants) (ref. 05-412, Millipore, USA; 1:1000), rabbit anti-AKT (ref. 9272, Cell Signaling, USA,
1:1000) and rabbit anti-phosporylated-AKT (p-S505AKT) (ref. 4054, Cell Signaling, USA,
1:1000), with 3% non-fat dry milk (Bio-Rad) in 0.05% PBST (PBS + Tween 20, Sigma-Aldrich)
overnight at 4°C. They were washed with double distilled water twice and incubated with sec-
ondary peroxidase-conjugated antibodies goat anti-mouse or goat anti-rabbit IgG (ref. A9044
and A0545, Sigma-Aldrich, USA, 1:5000) for 1.5 hours at room temperature. Membranes were
washed with PBST (2x10 minutes) and revealed with SuperSignal (Thermo Scientific). Western
blots of Drosophila and rat materials were quantified as previously described [24,44]. Bands
were scanned using a GS800 densitometer and Quantity One software (Bio-Rad). All measure-
ments were normalized to tubulin. Graphs represent the average of three independent Western
blot experiments.
The same Western blot protocol was employed for SH-SY5Y and neuronal cultures. Briefly,
cell wells were washed with PBS (4°C) and scrapped in 60 μl of lysis buffer (Cell Lysis Buffer,
ref. 9803, Cell Signaling). Once collected, cell lysates were heated, sonicated and clarified by
centrifugation at 17000 g. Protein concentration was measured using Bradford protein assay
and 60 μg of total protein were loaded into each SDS-PAGE lane. After blotting, membranes
were incubated overnight with the following antibodies: anti-Actin (ref. A2547, Sigma), anti-
GSK3 α/β (ref. 44-610, Invitrogen), anti-phospho-S9GSK3β (ref. 2435-1, Epitomics), anti-
Synapsin I (ref. 160 001, Synaptic Systems), anti-AKT (pan) (C67E7) (ref. 4691, Cell Signaling)
and the following polyclonal antibodies: anti-phospho-S473AKT1 (ref. NB600-590, Novus Bi-
ologicals), anti-β-Catenin (ref. 9562, Cell Signaling) and anti-phospho-β-Catenin (Ser33/37/
Synaptogenesis by GSK3β
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Thr41) (ref. 9561, Cell Signaling). Signal was detected using the corresponding IR-fluores-
cence-labelled antibodies (Li-Cor Bioscience, USA) and visualized and quantified with an Od-
yssey Infrared Imaging System (Li-Cor Bioscience). Unless otherwise indicated, all biochemical
experiments were performed adding the peptide at day 10 or 19 in vitro, cell lysis was done 48
hours later. The p-S473AKT and p-S9GSK3β values were related to the total AKT and GSK3β,
respectively. Synapsin and phospho-β-Catenin levels were related to Actin. Average changes in
phosphorylation and percentage of protein represent the normalized value with respect to the
control value, always included in the same Western-blot membrane. Values over 100 indicate
increase in protein levels and values below 100 indicate reduction.
PI3K activating peptides and GSK3 inhibitors. Activation of PI3K was achieved by a
transduction peptide (PTD4-PI3KAc) with the following sequence: YARAAARQAR-
AGSDGGpYMDMS [29,46–48]. This is a cell membrane permeable phosphopeptide com-
posed of a transduction domain of the tat family [48] fused to a SH2 interacting domain that
allows the activation of the class I PI3K independently from tyrosine kinase dimerization
[29,48–49]. Peptides were purchased either from GenScript (NJ, USA) or BioPeptide (FR).
GSK3 inhibitors: SB-415286 and AR-A014418 [50–52] were from Tocris, UK (ref. 1617) and
from Sigma, USA (ref. A3230), respectively.
Statistical analysis. All data are represented as mean ± s.e.m. Statistical significance was
calculated using a Student’s two-tailed t-test or ANOVA in DrosophilaWB. If p<0.05 in the
ANOVA test, a Bonferroni posthoc t-test was applied. The Kolmogorov-Smirnov test for nor-
mality was performed where appropriate, prior to the use of the Student’s two tailed t-test.
GraphPad Prism software package versions 3 and 6 (GraphPad, CA, USA) were used through-
out. Significant differences were noted by p<0.05, p<0.005 and p<0.0001.
Results
GSK3 modulates synapse number in Drosophila
We showed previously that the upregulation of shaggy/GSK3 reduces synapse number [28,31].
Here, we address the effects of down-regulating this gene and, for consistency, revisited the
upregulation experiments. To validate the genetic tools to up- (UAS-GSK3) or down-regulate
(UAS-GSK3DN or UAS-GSK3RNAi) the gene, we first quantified the expression changes of the
two protein isoforms in larvae: SGG39 and SGG10 [15]. Western blots from elav-Gal4, elav-
Gal4/UAS-GSK3 and elav-Gal4/UAS-GSK3RNAi larval central nervous systems (Fig. 1A) indi-
cate that the upregulation of GSK3 does not cause a significant increase of isoform SGG39 lev-
els (Fig. 1B), but a strong one (316 ± 36%, p<0.005) in the case of SGG10 isoform (Fig. 1C)
(n = 11 brains per lane in each genotype). In turn, the downregulation by GSK3RNAi decreases
the protein content to 50 ± 4% in SGG39 and to 58 ± 8% in SGG10 (p<0.05 and p<0.05 re-
spectively) (Fig. 1 B-C). Thus, both genetic tools effectively modify the gene expression.
To monitor the effects on synapse number, we confirmed that GSK3 overexpression reduces
synapse number by 22% (D42-Gal4/UAS-GSK3: 417±18, n = 13 larvae vs. D42-Gal4: 528±35,
n = 9 larvae; p = 0.0026) (Fig. 1D; S1A Fig., S1B). Next, we analyzed the downregulation ef-
fects: whereas the dominant negative form of GSK3 proved ineffective (not shown), the
GSK3RNAi caused a significant (p<0.0001) increase: 835±38 synapses (n = 7 larvae) when com-
pared to control: 528±35 synapses (n = 9) (Fig. 1D; S1B Fig.). Together, these data demon-
strate that the alterations of GSK3 levels elicit changes which are coherent with, and opposite
to, the direction of changes in the number of synapses.
Synaptogenesis by GSK3β
PLOSONE | DOI:10.1371/journal.pone.0118475 March 12, 2015 5 / 24
GSK3 is functionally downstream from AKT and PI3K in the
synaptogenesis pathway
As it is well known in several signaling pathways, PI3K modulates AKT activity. To confirm
the case in the Drosophila nervous system, we quantified Western blots of genotypes that up-
or down-regulate PI3K. The ratio p-S505AKT/AKT increases 35±18% (p<0.05) in brains
over-expressing PI3K (elav-Gal4/UAS-PI3K; n = 11 brains per lane in each genotype) and
decreases 22±10% (p<0.05) in brains over-expressing a dominant negative form of PI3K
Fig 1. Quantification of GSK3 isoforms levels and synaptic effects. A. Image from a representative immunoblot showing GSK3 levels in larval brains.
The antibody recognizes the two larval GSK3 isoforms SGG39 (upper band) and SGG10 (middle band). Tubulin is shown as load control (lower band).B.
Histograms show the content of SGG10 isoform in controls (elav-Gal4), GSK3 over-expressers (elav-Gal4/UAS-GSK3) and GSK3 under-expressers (elav-
Gal4/UAS-GSK3RNAi) normalized to Tubulin (n = 11 larval brains per lane, n = 3 independent Western blots). C. Histograms show the quantification of
SGG39 levels in the three genotypes as above. ANOVA test, *p<0.05, **p<0.005.D. Histograms indicate the total number of synapses quantified in GSK3,
up- or downregulation. Student's t-test, **p<0.005 ***p<0.0001.
doi:10.1371/journal.pone.0118475.g001
Synaptogenesis by GSK3β
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(elav-Gal4/UAS-PI3KDN) compared to control (elav-Gal4) (Fig. 2A, 2B). Thus, PI3K modu-
lates the phosphorylation state and, hence, the activity of AKT.
Next, we addressed the relationship between GSK3 and AKT. Drosophila has only one ser-
ine/threonine protein kinase encoding gene, Akt1 (dAkt1), homologous to mammalian c-Akt
[53]. Interestingly, as in vertebrates, Drosophila AKT inhibits GSK3 by specific phosphoryla-
tion of Serine 9 [54]. We asked whether changes in GSK3 could alter the phosphorylation levels
of AKT looking for a putative feedback effect. We quantified the ratio of p-S505AKT/AKT in
GSK3 up- or down-regulated genotypes. The data show that AKT phosphorylation is not af-
fected by changes in GSK3 expression (Fig. 2C-D). Thus, the synaptic effects of GSK3 manipu-
lations proceed through a feed-forward mechanism that does not involve changes in
AKT phosphorylation.
To address the functional relationship in vivo between PI3K, AKT and GSK3 in the context
of synaptogenesis, we tested their epistatic phenotypes. First, we confirmed the synaptic effects
of PI3K to allow a comparison with the subsequent double mutant combinations. As previously
reported, PI3K overexpression increases synapses (745±33, n = 8; p<0.0001) and its downre-
gulation decreases them (309±18, n = 8; p<0.0001) compared to control (528±35, n = 9)
(Fig. 3A).
Fig 2. Quantification of p-S505AKT/AKT ratio after up- or downregulation of PI3K or GSK3. A. Representative immunoblot showing p-S505AKT and
AKT in control (elav-Gal4), PI3K over-expressers (elav-Gal4/UAS-PI3K) and PI3K under-expressers (elav-Gal4/UAS-PI3KDN). B. Histogram showing the p-
S505AKT/AKT ratio in control and experimental larval brains. ANOVA test, * p<0.05.C. Representative Western blot showing p-S505AKT and AKT levels in
control (elav-Gal4), GSK3 over-expressers (elav-Gal4/UAS-GSK3) and GSK3 under-expressers (elav-Gal4/UAS-GSKRNAi) larval brains normalized to
Tubulin.D. Plot showing the corresponding p-S505AKT/AKT ratio in these genotypes (n = 11 larval brains per lane, n = 4 independent Western blots).
doi:10.1371/journal.pone.0118475.g002
Synaptogenesis by GSK3β
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Next, we assayed combinations of up and down expressions of PI3K and GSK3. The data in-
dicate that the reduction in synapse number elicited by GSK3 overexpression is epistatic over,
either the upregulation (D42-Gal4/UAS-PI3K/UAS-GSK3, 411±23, n = 8, p<0.005) or the
downregulation of PI3K (D42-Gal4/UAS-PI3KDN/UAS-GSK3, 265±24, n = 9, p<0.0001)
(Fig. 3A; S1C–E Fig.). These results indicate that, following the direct upregulation of GSK3
by genetic procedures, the synaptic effects of this enzyme are independent from any potential
regulation from PI3K. By contrast, the increase of synapse number elicited by the downregula-
tion of GSK3 is abolished and reversed when PI3K is down-regulated (D42-Gal4/UAS-PI3KDN/
UAS-GSK3RNAi, 355±40, n = 7, p<0.05), but maintained when PI3K is over-expressed (D42-
Gal4/UAS-PI3K/UAS-GSK3RNAi; 822±33, n = 7, p<0.0001) (Fig. 3A; S1D–E Fig.). Since the
genetic downregulation of GSK3 still leaves about 40% expression of both isoforms (Fig. 1),
these in vivo data are compatible with a regulatory role GSK3 upon PI3K activity in the context
of synaptogenesis. Thus, akin to other functional contexts, GSK3 and PI3K seem to share the
same pathway for synaptogenesis where GSK3 would be a negative modulator of PI3K without
evidences of a feedback regulatory loop.
Concerning the epistasia analysis between AKT and GSK3, we first confirmed that AKT
upregulation increases synapses (Fig. 3B and S1F Fig., D42-Gal4>UAS-AKT, 1012±48, n = 8)
compared with controls (D42-Gal4, 528±35, n = 9) (p<0.0001). The combined AKT
Fig 3. Effects of kinases on larval synapse number. A. Histograms indicate the total number of synapses
quantified in different GSK3 and PI3K combinations. B. Histograms show AKT overexpression and its
combination with GSK3 down- and up-expression. Student's t-test, *p<0.05, **p<0.005 ***p<0.0001.
doi:10.1371/journal.pone.0118475.g003
Synaptogenesis by GSK3β
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overexpression/GSK3 downregulation showed a synaptic increase of the same magnitude as
the stronger of the two, AKT (Fig. 3B and S1G Fig., D42-Gal4>UAS-AKT>UAS-GSK3RNAi,
1001±79, n = 9, p<0.0001). Finally, when GSK3 and AKT were simultaneously over-expressed
we obtained a modest but significant increase in synapse number (Fig. 3B, D42-Gal4>UAS-
AKT>UAS-GSK3, 667±65, n = 5, p<0.05). GSK3 combinations against a homozygous AKT
null background (D42-Gal4>UAS-GSK3; AKT–/– or D42-Gal4>UAS-GSK3RNAi; AKT–/–) were
not viable and, thus, we limited our study to AKT over expression condition only. Taken to-
gether, the data indicate that GSK3 levels do not modify the synaptogenic effects of AKT upre-
gulation, placing GSK3 functionally downstream of AKT in the synaptogenic pathway.
GSK3 inhibition can be achieved in mammalian neurons
We reasoned that, if GSK3 also participates in the PI3K-synaptogenic pathway of vertebrates,
then the GSK3 inhibition might result in a similar effect. We inhibited GSK3 activity through
two different approaches: 1) by stimulating its PI3K-AKT-dependent phosphorylation using
an engineered peptide, and 2) by its pharmacological inhibition using two high-affinity and se-
lective organic compounds.
To examine if the PI3K activator peptide can modulate GSK3β phosphorylation, we took
advantage of a PI3K previously characterized activation peptide (PTD4-PI3KAc; [29]) (seeMa-
terial and Methods) and quantified the levels of p-S473AKT and p-S9GSK3β [10], on SH-
SY5Y human neuroblastoma cell line cultures. Due to the presence of fetal serum in the culture
media, p-AKT levels are high under normal conditions; thus, to enhance the signal, cells were
serum starved for 16 hours prior peptide addition. The activity time course shows an increase
of p-S473AKT/AKT levels, reaching a 162±2% after 10 minutes and remaining stable with a
value around 140% for the rest of the experiment (240 min; Fig. 4A). In parallel, p-S9GSK3β/
GSK3β levels peaks after 30 minutes, reaching plateau (157±2%) for the rest of the experiment
(Fig. 4B).
As a positive control, we employed EGF, a bona fide tyrosine kinase activator. EGF induces
a rapid and large increase of p-S473AKT/AKT (229±3% after 10 min) that decreases to basal
levels (around 100% after 120 min). Levels of p-S9GSK3β/GSK3β show a similar profile with a
maximum of phosphorylation after 60 min (186±3%) and a later reduction to basal levels 240
min later (100%) (Fig. 4C). As a negative control, cells were treated with the transduction
PTD4 peptide without the PI3K activation domain (Fig. 4B). Similar results over p-S9GSK3β
were obtained with hippocampal neurons in culture: after 48 hours treatment with the PI3K ac-
tivator peptide, levels of p-S9GSK3β/GSK3β raised to a statistically significant, 127±4%
(p<0.0001), over control conditions (Fig. 4D). All together, these experiments validate the
PTD4-PI3KAc peptide as an effective tool to modulate GSK3 phosphorylation, and point out
to an important feature of the peptide: although the activation level of AKT is weaker than that
of a tyrosine kinase activator (EGF), its biological activity remains stable for a longer period of
time, up to 48 hours. Further, the data demonstrate that the activation of AKT by the peptide
results in GSK3β phosphorylation at Ser 9.
To pharmacologically block GSK3β, we used two specific organic inhibitors: AR-A014418
(AR) [50,55] and SB 415286 (SB) [51–52, 56] with an in vitro IC50 of 0.104 and 0.13 μM, re-
spectively. Prior to use them, we studied their potential toxicity over hippocampal neurons in
culture. Cell survival was quantified 48 hours after addition of different concentrations of both
drugs (S2A Fig.). SB did not affect neuronal density at a concentration range of 10 to 25 μM,
but the use of 50 μM resulted on a not statistically significant reduction of 13.8% on neuronal
survival (S2B Fig.). The second inhibitor, AR, did not affect neuronal survival at 1 and 10 μM,
while at 50 μM induced a significant neuronal death of 16.5% (p<0.05) (S2C Fig.).
Synaptogenesis by GSK3β
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Fig 4. The PI3K activator peptide PTD4-PI3KAc activates AKT and induces phosphorylation of GSK3 at S9. A. SH-SY5Y cell cultures were serum
starved for 16 hours and challenged afterwards with PTD4-PI3KAc 21 μM, EGF 10 ng/mL or PTD4 (control peptide at a concentration of 21 μM). Cells were
lysated at the indicated times and membranes incubated with anti-p-S473AKT and anti-p-S9GSK3β. Levels of phosphorylation were normalized to AKT and
GSK3β (lower band), respectively. B.Quantitative measurements of p-S473AKT (open circles) and p-S9GSK3β (closed circles) after PTD4-PI3KAc
treatment (n = 4). The level of p-S473AKT after PTD4 treatment (open triangles) is included as a negative control (n = 3). C.Quantification of p-S473AKT
(open circles) and p-S9GSK3β (closed circles) levels after EGF (10 ng/ml) treatment (n = 5). D. Hippocampal neuronal cultures of 12 DIV were treated for 48
hours with the PTD4-PI3KAc or PTD4 peptides. The treatment results in an average increase of p-S9GSK3β levels of 121 ± 3% (n = 7 from 7 different
cultures). Student’s two-tailed t-test, ***p<0.0001.
doi:10.1371/journal.pone.0118475.g004
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We next assayed the effectiveness of these drugs to inhibit GSK3 in hippocampal neurons in
culture. GSK3 regulate β-Catenin levels by phosphorylation at both Serine 33 and 37 and also
at Threonine 41 [57]. Since both organic compounds block the ATP pocket of all GSK3 iso-
forms [51], we monitored the relative levels of β-Catenin phosphorylation as a reporter of
GSK3 activity [36,58]. First, the ability of PTD4-PI3KAc to regulate phospho-β-Catenin levels
was tested. In neuronal cultures a treatment of 21 μM PTD4-PI3KAc for 48 hours reduced p-
β-Catenin levels by 19±2% (p<0.005) (Fig. 5A, 5C). The effects of AR were tested at 1, 2, and
10 μM (Fig. 5B). No significant changes were observed at 1μM; while 2 μM and 10 μM reduced
it 24±5% and 35±8%, respectively (p<0.05 in both experiments) (Fig. 5C). The simultaneous
activation of PI3K by PTD4-PI3KAc and the direct inhibition of GSK3 with AR did not result
in a further inhibition of GSK3β pathway, with an average reduction of 32±5% (p<0.005),
25±9% (p<0.05), and 24±7% (p<0.05) at 1, 2 and 10 μM of AR respectively, suggesting that
both drugs act over the same pathway (Fig. 5C). The efficiency of SB inhibiting GSK3β was
tested at 1, 10 and 25 μM, the levels of p-β-Catenin decreased in a 26±6% (p<0.05), 28±9%
(p<0.005) and 38±8% (p<0.005) respectively (Fig. 5D, 5E). Similar to AR, co-treatment
of PTD4-PI3KAc and SB did not further decrease the phosphorylation levels of β-Catenin
(17±5% (p<0.05), 25±8% (p<0.05) and 39±10% (p<0.05) at 1, 10 and 25 μM of SB, respective-
ly; Fig. 5E). In conclusion, PTD4-PI3KAc and the inhibitors AR and SB effectively inhibit
GSK3β at the selected dose.
GSK3 inhibition exhibits an age-dependent effect on mammalian
synaptogenesis
The density of synapses was evaluated by immunocytochemistry on hippocampal cultures
(Fig. 6A). The overlap of two presynaptic markers (Bassoon, a scaffold protein, and Synapsin,
a vesicular component) was used as criteria for mature synapses as previously described
[29,59]. We employed fully developed cultures of 21 DIV, applying the treatment at day 19 and
counting synapses at day 21. At this age, PTD4-PI3KAc (21 μM) induced an augmentation of
synaptic density (Fig. 6B, 6C) to 125±4% (statistically significant, p<0.0001). This observation
is in agreement with our previous data showing an increase in both excitatory and inhibitory
synapses following PI3K up-regulation [29]. Conversely, GSK3β inhibition by AR 10 μM in-
creased synaptic density to 116±v5% (p<0.05) (Fig. 6B) and SB raised synaptic density to
112±5% (ns) and 133±5% (p<0.0001) at 10 and 25 μM respectively (Fig. 6C). To investigate
potential cooperative effects, we analyzed the simultaneous activation of PI3K and inhibition
of GSK3. The combined treatment of PTD4-PI3KAc with AR results in an increase of 113±5%,
ns, while the use of SB resulted in synapse density raises of 120±5% (p<0.05) and 137±6%
(p<0.0001), 10 and 25 μM respectively. In these three cases, the increase was similar to the in-
dividual treatments (Fig. 6B, 6C); suggesting that GSK3 should be downstream from, and in
the same pathway of PI3K in the context of synaptogenesis.
In younger (12 DIV) cultures, PI3K activation resulted also in the expected synaptic in-
crease, 126±6% (p<0.0001) (Fig. 6D). However, the inhibition of GSK3 by AR or SB reduced
synapse number instead as observed in older cultures. SB at 10 and 25 μM reduced synaptic
density to 74±12% (p<0.05) and 79±4%, (p<0.0001) respectively (Fig. 6D), and AR reduced it
to similar values (90±4%; p<0.05) (Fig. 6D). As it seems, the strong pro-synaptogenic effect
elicited by GSK3 inhibition in 21 DIV cultures (see 25 μM SB treatment in Fig. 6C), is opposite
to the effect obtained with the same drug and dosage in 12 DIV cultures (Fig. 6D). To assess
the independence of PI3K and GSK3 in the process, we measured synaptic density after a com-
bined treatment with SB and PTD4-PI3KAc. The results indicate that activation of PI3K
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compensates the reduction of synaptic density caused by GSK3 inhibition (statistically signifi-
cant, p<0.0001 when compared with SB alone), yielding mean values of 105±10 and 115±4%
(10 and 25 μM of SB respectively), which are not significantly different from culture controls
Fig 5. GSK3 inhibition results in a decrease of p-β-Catenin. A. Immunoblot of p-β-Catenin from 12 DIV hippocampal neurons treated for 48 hours with
PTD4-PI3KAc or PTD4 (21 μM). B. Immunoblot of p-β-Catenin after AR-A014418 treatment, alone or in combination with PTD4-PI3KAc (21 μM).
Phosphorylation levels were normalized to the total actin. C. Plot bar representing the mean average of p-β-Catenin after the described treatment. All
percentages are referred to control conditions as 100%, always included in eachWestern-blot membrane. Only the treatment with 2 and 10 μM of AR-
A014418 decreased p-β-Catenin levels. The co-treatment with the PI3K activator did not induce a further reduction.D. Immunoblot of p-β-Catenin after SB
415286 or in combination with PTD4-PI3KAc (21 μM) treatments. E. Plot bar of the percentage of p-β-Catenin after treatment with SB 415286. Exposure of
cells to SB 415286 or in combination with PI3K activator led to a statistically significant decrease in p-β-Catenin (n = 15 from 15 different cultures).
Percentage of p-β-Catenin was normalized to the total Actin levels. Significance refers to the statistical analysis of the experiments versus the control (100%).
Student’s two-tailed t-test, *p<0.05, **p<0.005.
doi:10.1371/journal.pone.0118475.g005
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Fig 6. Differential effects of GSK3 inhibition on synaptic density. A. Example of a 21 DIV hippocampal neuron in culture. Scale bar = 10 μm. Bottom
pictures: detailed magnification of the area depicted by the white box. Synapses (a) were localized following a double criterion: puncta positive for Synapsin
(b, red) and for Bassoon (c, green). Scale bar 3 μm. B. Plot graph of the average changes in synaptic density at 21 DIV after AR-A014418 treatment. PTD4-
PI3KAc and PTD4 were used at 21 μM. C. Plot graph of the results of synaptic density after the GSK3 inhibition by SB 415286 treatment.D.Quantification of
Synaptogenesis by GSK3β
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conditions (Fig. 6D). Thus, PI3K is not involved in the age-dependent effect caused by
GSK3 inhibition.
To analyze the age-dependent effect of GSK3 inhibition through an alternative method, we
quantified the levels of two synaptic proteins, Synapsin and PSD95, by Western blot. Synapsin
is the major component of the presynaptic vesicles and its expression has been used as a report-
er of synaptogenic activity [29]. Protein levels were quantified from high-density cultures treat-
ed during 48 h, either with inhibitors alone or in combination with the PI3K activating peptide.
In 21 DIV cultures, activation of PI3K up-regulates Synapsin by 129±2% (p<0.05). Moreover,
GSK3 inhibition by SB, the most robust inhibitor, raised Synapsin to 142±2% and 166±2% (10
and 25 μM of SB, p<0.05 and p<0.005 respectively; Fig. 7A, 7B). The simultaneous activation
of PI3K and inhibition of GSK3 resulted in a similar degree of augmentation, with mean values
of 137±1% (p<0.005) and 141±2% (p<0.05) (Fig. 7B). These changes in Synapsin levels are
consistent with the variation in synapse density (see above, Fig. 6D).
In 12 DIV cultures, PI3K activation increased Synapsin by 126±4%, the same effect as in the
aged cultures (see above). By contrast, GSK3 inhibition by SB (1, 10 and 25 μM) did not result
in a significant change of Synapsin levels (Fig. 7C, 7D) as it was observed in the aged cultures
(Fig. 7B). Similar to 21 DIV, the simultaneous PI3K activation by the peptide and GSK3 inhibi-
tion by SB, at all concentrations tested, did not elevate Synapsin in young cultures (Fig. 7D).
These effects on Synapsin expression were reproduced with AR (Fig. 7E, 7F). In this case, nei-
ther the 2 or 10 μMAR treatments, nor their combination with PTD4-PI3KAc, modified
Synapsin levels (Fig. 7F).
In addition, we tested another synaptic protein, PSD95, which is a component of the gluta-
matergic postsynaptic side and obtained similar effects (Fig. 8). In 21 DIV cultures GSK3 inhi-
bition by SB raised expression levels to a 128±3% (p<0.005) and the joint activation of PI3K
plus the inhibition of GSK3 resulted also in a significant increase of 148±1% (p<0.05). By con-
trast, the same treatments applied in 12 DIV cultures did not result in significant changes in
PSD95 (90±5%, with SB, and 99±1% in the PTD-PI3KAc + SB treatments), (Fig. 8A, 8B).
Therefore, we conclude that GSK3 inhibition has a differential effect repressing/enhancing syn-
apse formation depending on neuron age and this effect is not related to PI3K.
GSK3 regulates spine formation
Dendritic spines are postsynaptic specializations whose number has been associated with learn-
ing and memory processes [60]. The increase in synaptic density found in 21 DIV cultures
prompted us to consider whether spine density was also up-regulated by GSK3 inhibition.
GSK3 has been located in spine densities associated to AMPA receptors, location compatible
with a role regulating synaptic plasticity and spine formation [19].
We first examined the localization of p-S9GSK3β in hippocampus neurons transfected with
GFP-Actin [61]. The expression vector was under control of a PDGF neuronal promoter to
avoid excessive protein expression [45]. After 19 DIV, the GFP-Actin signal was concentrated
at the spine domains that facilitate their identification. Under these conditions, p-S9GSK3β
was found in dendrites and in most spines (Fig. 9A). To discriminate if the protein could local-
ize also in the presynaptic compartment we co-immunolocalized Bassoon. The images indicate
that p-S9GSK3β is not associated with the presynaptic side (Fig. 9B).
synaptic density at 12 DIV after treatments with PTD4-PI3KAc, AR-A014418, SB 415286 alone or in combination with PTD4-PI3KAc. Percentage of change
refers to PTD4 control treatment. Cultures were treated for 48 hours before fixation (n = 10–12 from 3 different cultures). Significance refers to the statistical
analysis of each experimental condition versus PTD4 treated cultures (100%) Student’s two-tailed t-test, *p<0.05, **p<0.005, ***p<0.0001.
doi:10.1371/journal.pone.0118475.g006
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Fig 7. GSK3 inhibition modifies Synapsin levels. A. Representative immunoblot showing Synapsin levels after GSK3 inhibition by SB 415286 treatment in
21 DIV neuronal hippocampal cultures.B. Plot graph summary of the results of 21 DIV cultures. The bars are the average levels of Synapsin versus control
conditions after the indicated treatments, alone or in combination with PTD4-PI3KAc (21 μM). C. Representative immunoblot for Synapsin after GSK3
Synaptogenesis by GSK3β
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To quantify the effects of GSK3 inhibition over spine density, culture neurons were treated
with a broad range of SB concentrations from 0.5 to 25 μM for 48 hours (Fig. 9C; [62]). Similar
to the case of culture age (see above) GSK3 inhibition by SB has a differential effect over spine
density, albeit now dependent on dosage. Thus, 1 to 25 μM SB, produced a dosage-dependent
reduction in spine density ranging from 84±9 (p<0.05) to 68±2% (p<0.0001) (Fig. 9D). Inter-
estingly, when cultures were treated with the lowest concentration (0.5 μM) spine density ex-
hibit an opposite effect, a significant increment of 16±5% (p<0.005) (Fig. 9D). Likely, age and
dosage are just two among the several factors that may account for the diversity of synaptic re-
sponses to GSK3 inhibition.
Discussion
We have addressed the role of GSK3 in synaptogenesis and spinogenesis in a comparative
study between the neuromuscular junction of Drosophila larvae and cultured hippocampal rat
neurons. The data indicate that GSK3 inhibition in both species leads to a synaptic increase
through a PI3K signaling pathway, in which GSK3 represses synapse formation.
In flies, synapse number increases when GSK3 is down-regulated or when PI3K is up-regu-
lated. In the epistasis analysis, same phenotype combinations are not additive which strongly
suggests that both kinases share the same pathway. However, these data do not inform about
their hierarchical order. Opposite phenotype combinations could have solved the functional
inhibition in 12 DIV culturesD. Plot graph of Synapsin after SB 415286 treatment, alone or in combination with PTD4-PI3KAc (21 μM). E. Representative
immunoblot of Synapsin after GSK3 inhibition by AR-A014418 in 12 DIV cultures. F. Plot bars of the average levels of Synapsin after AR-A014418 treatment,
alone or in combination with PTD4-PI3KAc (21 μM). Percentage of Synapsin was normalized to the total Actin levels. n = 10–15 from 6 different cultures.
Significance refers to the statistical analysis of the experiments versus the control (100%). Student’s two-tailed t-test, *p<0.05, **p<0.005, ***p<0.0001.
doi:10.1371/journal.pone.0118475.g007
Fig 8. GSK3 inhibition affects PSD95 expression. A. Representative immunoblots of PSD95 levels after GSK3 inhibition by SB 415286 treatment
employing 12 or 21 DIV cultures.B. Plot graph summary of the results of 12 and 21 DIV cultures. The bars are the average levels of PSD95 versus control
conditions after SB 415286 treatments, alone or in combination with PTD4-PI3KAc (21 μM). Percentage of PSD95 was normalized to the total Actin. n = 4–5
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Fig 9. Localization of p-S9GSK3β at the synapse and spine effects of its inhibition. A. p-S9GSK3β localizes at the postsynaptic side. Left: Single
confocal microscopy image of a GFP-Actin transfected neuron counterstained with p-S9GSK3β in red and nuclei in blue (DAPI). Note that the cell body of the
transfected neuron is not in the same focal plane (bottom right corner of the image). Scale bar = 5 μm. Right:High magnification view of the area depicted in
the white box showing the (a) Merged picture of (b) p-S9GSK3β in red and (c) Actin-GFP signals in green. Positive spines for p-S9GSK3β are indicated by
white arrowheads. Scale bars = 3 μm. B. p-S9GSK3β does not colocalize with presynaptic Bassoon. Left: 21 DIV old hippocampal neuron stained with
p-S9GSK3β in red, Bassoon in green and nuclei in blue (DAPI). Scale bar = 5 μm. Right panels: high magnification view of the area depicted in the white
box showing (a) Merged picture of (b) p-S9GSK3β in red and (c) Bassoon in green. Notice the total absence of colocalization between both markers. Scale
bar = 3 μm. C. GSK3 inhibition has a differential effect on spine density. Actin-GFP transfected neurons of 19 DIV were treated for 48 hours with different
concentrations of SB 415286. a, b, c, d, e, Dendritic fragments of a control (top), 0.5 μM, 1 μM, 10 μM and 25 μM of SB 415286 treated neurons, respectively.
D. Plot graph summary of the effects on spine density [number of cultures: n = 3 (0.5 μM); n = 4 (1 μM); n = 3 (10 μM); n = 2 (25 μM)]. Average number of
spines were compared and normalized in front of control cultures. Student’s two-tailed t-test, *p<0.05, **p<0.005, ***p<0.0001.
doi:10.1371/journal.pone.0118475.g009
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hierarchy. One of these combinations—joint upregulation of PI3K and GSK3 -, produced the
phenotype of GSK3 alone, while the other combination—joint downregulation of PI3K and
GSK3-, yielded the phenotype of PI3K alone (Figs. 1D and 3A). Both results could be ex-
plained taking into account the respective amounts of both proteins. Thus, while GSK3 overex-
pression increases three fold the amount of Sgg10 isoform (Fig. 1B), PI3K upregulation
increases p-S505AKT by 35% only (Fig. 3B). This excess of GSK3 might not be effectively in-
hibited by a lesser amount of p-S505AKT, with the final result of a decrease in synapse number
due to the GSK3-dependent antisynaptogenic effect. In the second combination, the joint
downregulation of PI3K and GSK3, the PI3K phenotype prevails. This result can also be ex-
plained through the relative protein levels elicited by the genetic tools. The RNAi against GSK3
yields a reduction of 50% in the total amount of both GSK3 isoforms, Sgg10 and Sgg39
(Fig. 1B-C). By contrast, PI3KDN reduces pS505-AKT around 22% (Fig. 3B). In this case, the
amount of p-S505AKT could not be enough to phosphorylate, hence inhibit, all the GSK3 pro-
tein, leaving a sufficiently activated level of GSK3 to finally cause a reduction in the number of
synapses. Additionally, we cannot formally rule out the possible differences between the use of
dominant negative and RNAi constructs to reduce expression levels of these kinases, taking
into account that, whereas the first interferes with protein function, the second attenuates pro-
tein transcription. To assess this variability in the available genetic tools, we do not observe
changes in synapse number when we use GSK3DN but we observe satellite boutons as previous-
ly described ([32], data not shown). Moreover, when AKT overexpression is combined with
GSK3RNAi we do not find an additive effect (Fig. 2C) in agreement with the previous analysis
of PI3K and GSK3 (Fig. 2B).
The three kinases, PI3K, AKT and GSK3 seem to share the same pathway for synaptogenesis
because all their same phenotype combinations do not show additive effects (Fig. 3A, 3B).
Also, the p-S505AKT/AKT ratio does not change in larval brains that over- or down-regulate
GSK3 (Fig. 2D), suggesting again that GSK3 is downstream from AKT and does not affect
AKT phosphorylation. This scenario from Drosophila neurons is consistent with evidences
from other cell types and functional contexts [36].
In vertebrates, GSK3 has been implicated in several neuronal functions [11] and diseases
[36]. Referring to pathological conditions, the high levels of GSK3 in Alzheimer disease and the
cognitive deficits that these patients show can be interpreted in the light of the reduction of
synapse number that flies and rodents exhibit under genetic or pharmacological conditions.
However, could a molecular mechanism be proposed to link GSK3 signaling and synapse loss?
In mammals, the Wnt/Dvl/GSK3 pathway is implicated in synapse formation [34]. GSK3 α
and β are canonical components of this pathway; Wnt binds to Frizzled-LRP5/LRP6 corecep-
tors causing Dvl activation and displacing GSK3β from its complex with APC, Axin and β-
Catenin. This allows β-Catenin targeting to the nucleus where it regulates gene transcription
[63–64]. In the absence of Wnt, GSK3β represses this cascade, leading β-Catenin to degrada-
tion [36]. Supporting the role of Wnt-GSK3 on synaptogenesis, neurons over-expressing Dvl
present a large number of Synapsin clusters in cerebellum, whereas hippocampal neurons
treated with soluble Wnt7b show an increase in Bassoon presynaptic clusters [23]. GSK3 inhi-
bition by lithium mimics Wnt7a signaling by inducing axonal remodeling and Synapsin clus-
tering [7]. Furthermore, in vivo studies have demonstrated that structural plasticity changes
induced by enriched environment are regulated through Wnt7a/b [65]. Also, Wnt7 injection in
the hippocampus increases the number of synaptic terminals, whereas perfusion of the Frizzled
receptor antagonist, s-FRP1, blocks the effects of an enriched environment over structural plas-
ticity and reduces synapse number [65]. To date, however, no studies had been carried out to
analyze the effects of directly inhibiting GSK3 over synaptic density. Here, we regulated GSK3β
activity by two different procedures, indirectly, employing a PI3K activator peptide, through
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the PI3K-AKT-mediated phosphorylation of GSK3 at Serine 9 [66], and directly by blocking
kinase GSK3 activity with two chemical inhibitors.
In mature cultures (21 DIV), PI3K activation or direct GSK3 kinase inhibition induced an
increase of synapse number, concomitantly with an increase of Synapsin and PSD95 expres-
sion. The lack of an additive effect of the conjoint activation of PI3K and GSK3 inhibition, sug-
gest that both kinases share the same pathway. Results in both species confirm a direct role of
GSK3 regulating synapse formation and suggest that, under physiological conditions, GSK3 ac-
tivity represses synapse formation. Inhibition of GSK3 up-regulates PSD95 or Synapsin indif-
ferently, suggesting that GSK3 could operate downstream from PI3K/AKT in the pathway that
leads to synapse formation.
When the same experimental procedure was performed in 12 DIV hippocampal neurons,
inhibition of GSK3 by PI3K-AKT activation led to an increase of PSD95 and Synapsin expres-
sion and a concomitant raise in synaptic density. In contrast, blocking GSK3 kinase activity in-
duced a reduction of synaptic density without affecting Synapsin or PSD95 levels.
Concerning spine density, it has been previously demonstrated that PI3K activation in-
creases spinogenesis both in cultures and in brain hippocampus [29,61,67]. Here, whereas the
GSK3 inhibitors raised synaptic density in older cultures, the same range of concentrations re-
duced spine density and only the lowest concentration up-regulated spine density. Similar re-
sults over spine density were reported previously using a related inhibitor of GSK3 [68]. Thus,
neurons treated with oligomeric Aβ peptides showed a pronounced spine loss, while the phar-
macological inhibition of GSK3 rescued spine loss. Yet, excessive inhibition of GSK3 resulted
again in a reduction of spine number [55]. On the mechanism of spine loss by GSK3 inhibition,
at this point we can only speculate with an interaction of postsynaptic GSK3 with actin poly-
merization [69]. Further experiments analyzing actin polymerization in spines will be required
to clarify this point. It is plausible, however, that synaptogenesis and spinogenesis will be sus-
tained by non-identical mechanisms.
Why GSK3 inhibition can repress/enhance synaptic formation depending on the age of the
cultured neurons? To answer this question we must consider that GSK3 regulation can be inde-
pendent from AKT phosphorylation. Indeed, downstream of PI3K, GSK3 is inactivated via
AKT-mediated phosphorylation of two serine residues (serine 21 for GSK3α and serine 9 of
GSK3β; [36]). When both native α and β GSK3 are replaced by mutant isoforms resistant to in-
hibitory PI3K/AKT phosphorylation, the resulting double GSK3 knock-in mice develop nor-
mally with no defects in their nervous system [70] and cultured hippocampal neurons polarize
normally [55]. However, blocking GSK3 by isoform-specific inhibitors alters neuron polariza-
tion and induces formation of multiple axons [7]. Recently, Gobrecht and colleagues have dem-
onstrated that GSK3 knock-in mice show an accelerated axonal growth of Dorsal Root
Ganglion (DRG) neurons both in culture and in vivo, an effect that was impaired by the use of
a direct GSK3 kinase inhibitor (i.e. SB) [56]. Furthermore, another recent work on DRG senso-
ry axons showed that regenerative properties do not depend of GSK3 phosphorylation. Inter-
estingly, the inhibition of PI3K in these neurons results in a potentiation of GSK3 kinase
activity, pointing out the existence of an alternative PI3K-dependent pathway to inhibit GSK3
[71]. All together, these findings suggest that AKT-mediated phosphorylation might not be
the only mechanism by which GSK3 is inactivated in neurons downstream of PI3K. The levels
of GSK3 expression, rather than its phosphorylation status, might determine its activity in
neurons.
Alternatively, a possible change in Wnt signaling along hippocampal cell culture develop-
ment could also be responsible for the observed differential GSK3 effects. Wnt and PI3K-AKT
pathways share a common element, Axin, which binds to GSK3 preventing its phosphorylation
and the subsequent inhibition by AKT [72]. Inhibitors binding to the catalytic pocket of GSK3
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could regulate GSK3 independently of Axin function and AKT phosphorylation [73]. Develop-
mental changes either in the level of GSK3 expression or apparent affinity for the Wnt-Axin
complex should modulate GSK3 activity. Future experiments characterizing the synaptogenic
PI3K role in the double GSK3 knock-in mice would be helpful to clarify this point.
Other authors have also proposed an additional layer of GSK3 regulation based on the exis-
tence of “primed” or “not primed” substrates. The prior phosphorylation of many GSK3 targets
enhances GSK3 affinity and binding to such primed substrates [52,74–75]. Thus, a develop-
mentally regulated expression of GSK3-phosphorylated substrates may explain the differential
effects of the chemical inhibitors. It is worth noting, however, that PI3K activation exerts a
synaptogenic role independently of culture age ([29], this paper).
In summary, this study shows that GSK3β regulates synapse number in flies and rodents
through a signaling pathway that includes PI3K and AKT. In view of this conservation, it
seems justified to consider GSK3 as a potential target for the treatment of several CNS diseases
[50]. Nevertheless, a word of caution is necessary concerning the use of inhibitors and their
dosage in the light of the observed differential responses according to neuronal culture age and
the differential effect over spine density. It is plausible that the failure of the GSK3-inhibition-
based treatments for Alzheimer's disease may have been due to the ongoing hippocampal neu-
rogenesis and, thus, cell stage heterogeneity [76].
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S1 Fig. GSK3, PI3K and AKT modify synapse number. Representative confocal images of
larval motor neurons double immunostained against α-HRP (red) and nc82 antibody (green)
from A. Control (D42-Gal4) B. GSK3 downregulation (D42-Gal4/UAS-GSK3RNAi) C. Simulta-
neous overexpression of GSK3 and PI3K (D42-Gal4/UAS-GSK3/UAS-PI3K)D. Simultaneous
downregulation of GSK3 and PI3K (D42-Gal4/UAS-GSK3RNAi/UAS-PI3KDN) E. Simultaneous
overexpression of PI3K and downregulation of GSK3 (D42-Gal4/UAS-PI3K/UAS-GSK3RNAi)
F.Overexpression of AKT (D42-Gal4/UAS-AKT) and G. Simultaneous overexpression of AKT
and downregulation of GSK3 (D42-Gal4/UAS-AKT/UAS-GSK3RNAi). A high magnification
view from the white square in E is shown in the upper right corner. Scale bars = 10 (A-G) and
2 μm (insert in E).
(TIF)
S2 Fig. Dosage-dependent toxicity of GSK3 inhibitors. A. Representative confocal images of
hippocampal neuronal cultures in control conditions and after treatment with the indicated
concentrations of SB 415286 or AR-A014418. Neuronal density was quantified from high-reso-
lution images comprising 40 individual pictures (8 x 5 fields, around 12 mm2). The pictures
only show a detailed area of 6 mm2. Neuronal staining by MAP2B is shown in green and nucle-
ar staining by DAPI is shown in red. DAPI marks all cells in the culture, astrocytes and neu-
rons, while MAP2B marks only neurons. Scale bar = 50 μm. B. The effects of SB 415286 over
neuronal survival were tested after 48 hours at three concentrations (10, 25 and 50 μM) and
compared with control conditions (white histogram) in 12 DIV hippocampal neurons. C. Simi-
lar experiments were performed employing AR-A014418 (1, 10 and 50 μM) (n = 4 coverslips
from 3 different cultures). Student’s two-tailed t-test, p<0.05.
(TIF)
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